IJGC Podcast

By BMJ GroupMedicine Health & Fitness

IJGC Podcast episodes

June 30, 2022 Consensus Statement on Pre-Invasive Vulvar Disease with Mario Preti
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Mario Preti to discuss the ESGO, ISSVD, ECSVD, and EFC consensus statements on pre-invasive vulvar lesions. Dr. Preti received his Specialization in Gynecology and Obstetrics and Specialization in Medical Oncology at the University of Torino. He is Associate Professor at the Department of Surgical Sciences, University of Torino, Italy, and the Immediate Past President of the ISSVD (International Society for the Study of Vulvo-vaginal disease). Dr. Preti is the author of 4 books on vulvo-vaginal diseases, and as of June 2022, he has published 108 papers indexed in Scopus/Pubmed, with 2,014 citations and an H-index of 23.
Highlights:
Epidemiological data show no decrease in vulvar invasive cancer incidence. This means that accurate diagnosis and treatment of pre-invasive vulvar disease must be improved: these are among the ESGO-ISSVD-ECSVD aims.
The two carcinogenic pathways of vulvar squamous neoplasia recognize as precursors two vulvar intraepithelial neoplasia (VIN): HPV-associated squamous intraepithelial lesions (High Grade VIN) and HPV-independent VIN (mainly differentiated VIN). These precursors have different clinical approach, treatment and oncological risk. Their histologic features can be subtle, and the histological diagnosis may be further complicated by coexisting conditions.
For differentiated VIN, an excisional procedure must always be adopted. Medical treatment (imiquimod or cidofovir) and ablative treatment can be considered for high grade VIN to preserve anatomy and function. These conservative approaches must be preceded by representative biopsies to exclude invasive disease.
Follow up should be modulated according to the risk of recurrence (type of lesion, patient age and immunological conditions, other associated lower genital tract lesions).
Pre-invasive vulvar lesions deserve specific attention because they affect not only functionality and body image, but also psychosexual factors.
38 min
June 29, 2022 Imiquimod vs Surgery RCT in Vulvar VIN
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Gerda Trutnovsky to discuss the use of imiquimod versus surgery for the treatment of vHSIL. Dr. Trutnovsky studied at the University of Graz/Austria and the University of Sydney/Australia. She works as an associate professor in the Department of Obstetrics and Gynecology at the Medical University of Graz/Austria, with a special interest in vulvar disease.
Highlights:
This was the first prospective trial of imiquimod versus surgery for the treatment of vulvar high grade squamous intraepithelial lesions (vHSIL).
Complete clinical response at 6 months was observed in 80% of patients using imiquimod per-protocol, compared to 79% in women who had one surgical intervention.
Imiquimod was used in a slowly escalating dosage scheme up to 3 times a week and reduced in case of side effects – local toxicity was mostly mild to moderate.
Imiquimod is a safe, effective and well accepted alternative to surgery and can be considered a first-line treatment option.
28 min
June 28, 2022 Surgical Staging Advanced Cervical Cancer
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Dimitrios Nasioudis. Dr. Nasioudis is a Gynecologic Oncology Fellow at the University of Pennsylvania. His current research focuses on translational therapeutics and population-based research.
Highlights:
The utility of surgical staging for patients with locally advanced cervical cancer has not been established.
While PET-CT is the most sensitive imaging modality to detect para-aortic metastases, the false negative rate can be as high as 20%.
In the United States, surgical staging for locally advanced cervical cancer is rarely performed with a decreasing utilization.
The impact of surgical staging on the oncologic outcomes is not clear.
31 min
June 17, 2022 Mentor’s Podcast: Andreas Obermair
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Andreas Obermair. Dr. Obermair is a gynecological oncologist in Brisbane, Australia, promoting surgery with proven better patient outcomes.
Highlights:
- Facing and dealing with adversity in life
- Goals for making gynecological oncology safer, less invasive, and smarter; ensuring that patients are not scared of treatment; and increasing the effectiveness of treatment
- Exploring novel options of therapy and seeking strategies for newer treatments. Only if we are not satisfied with what we do today can we hope to achieve a better outcome tomorrow.
1 hr 1 min
June 14, 2022 Fertility-sparing Neoadjuvant Chemotherapy in ＞4cm Cervical Cancer with Dr. David Viveros-Carreño
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. David Viveros-Carreño. Dr. Viveros-Carreño is a Gynecologic Oncologist at Instituto Nacional de Cancerología, Clínica Universitaria Colombia and Clínica Los Nogales in Bogotá, Colombia.
Highlights:
- Fertility-sparing surgery after neoadjuvant chemotherapy in cervical cancer >4 cm is feasible, but the evidence is limited and should be considered as an experimental intervention.
- A complete pathological response occurred in 56% of patients.
- At least one pregnancy was achieved in 67% of cases and 60% were pre-term deliveries.
30 min
June 01, 2022 End of Life Care in Gynecologic Oncology
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Katherine Hicks-Courant, MD, MSHP. Dr. Hicks-Courant is a fellow in the Division of Gynecologic Oncology at the University of Pennsylvania. She studies the intersection of gynecologic oncology, palliative care and oncology care delivery systems.
Highlights:
Having a gynecologic rather than a medical oncologist was associated with lower rates of high-intensity end-of-life care.
Having a gynecologic oncologist rather than a medical oncologist was associated with higher rates of invasive procedures.
Having a gynecologic oncologist rather than a medical oncologist was associated with higher Medicare spending.
35 min
June 01, 2022 Conservative Management of Cervical Cancer with Rene Pareja
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Rene Pareja to discuss conservative management of cervical cancer. Dr. Pareja is a gynecologist-oncologist at Astorga Oncology Clinic in Medellín and the National Cancer Institute in Bogotá, Colombia. He is a reviewer for more than 20 specialty journals, an Associate Editor for IJGC, a member of the Editorial Board of Gynecology Oncology, and a member of the board of directors of the International Gynecological Cancer Society (IGCS). Additionally, he is a member of FIGO committee on Women's Cancer. Dr. Pareja is the author of nine book chapters and more than 70 publications in peer-reviewed journals, and at IGCS 2021 he received an award for Community Advancement in Resource-Limited Settings.
Highlights:
1. Fertility preserving options have to be offered to all women wishing to preserve their fertility potential, that fulfil the ECOG status, histological, and imaging criteria.
2. It is recommended to have an evaluation by human reproduction specialized teams in order to rule out any potential impairment before the surgery.
3. The relapse rate for vaginal radical trachelectomy, abdominal radical trachelectomy and simple trachelectomy/conization are around 4-5%.
4. The highest live birth rates are seen in patients undergoing conization + lymph node assessment (over 88%).
5. Vaginal radical trachelectomy and minimally invasive radical trachelectomy, with preservation of ascendent branch of uterine artery, are contraindicated in women with tumors > 2 cm, due to the high rate of relapse (over 20%).
31 min
May 24, 2022 SOLO1-The 5-year Follow Up Data with Dr. Susana Banerjee
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Susana Banerjee to discuss SOLO1. Dr. Banerjee is a Consultant Medical Oncologist and Research Lead for the Gynaecology Unit. She is also Reader in Women’s Cancers at the Institute of Cancer Research. Dr Banerjee specialises in ovarian cancer and the systemic treatment of endometrial and cervical cancers.
Highlights:
- This report is the longest follow-up period for a PARP inhibitor in the newly diagnosed advanced ovarian cancer.
- The present analysis shows a PFS benefit that is sustained for several years following completion of 2 years of maintenance olaparib.
- PFS benefit was consistent irrespective of higher or lower clinical risk or BRCA1 or BRCA2 mutation.
- SOLO1 is the first to report longer-term follow-up for safety in patients with newly diagnosed ovarian cancer receiving a PARPi as maintenance treatment.
- The safety profile for patients in the maintenance olaparib remained consistent with that reported previously, with no new safety signals. Importantly, no additional cases of MDS or AML were reported.
35 min
May 18, 2022 The ALICE Trial with Glauco Baiocchi Neto
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Glauco Baiocchi. Dr. Baiocchi is the Director of the Department of Gynecologic Oncology at the AC Camargo Cancer Center in Sao Paulo, Brazil.
Highlights:
-SLN biopsy has emerged as an accurate method for lymph node staging in endometrial cancer.
-Prospective studies aimed to analyze the performance of SLN biopsy in staging endometrial cancer rather than oncological outcomes.
-ALICE trial aims to confirm that SLN mapping without systematic node dissection does not negatively impact oncological outcomes.
34 min
May 09, 2022 Mentor’s Podcast: Jalid Sehouli
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Jalid Sehouli. Dr. Sehouli is director of the department of gynecology with center of oncological surgery at Charité Medical University in Berlin. He founded the first certified ovarian cancer center in 2007, published more than 500 articles, and is a teacher and a writer of several belletristic books.
Highlights:
Gynecology should be always holistic, interdisciplinary, and multi-professional.
Research in gynecology relies on teamwork, and international collaboration is essential.
The most relevant drug in medicine is communication!
1 hr 11 min

About IJGC Podcast

From the publisher's feed

The International Journal of Gynecological Cancer (IJGC) podcast explores the latest research on detection, prevention, diagnosis, and treatment of gynecologic malignancies. Enjoy interviews with leading experts as they discuss novel and relevant topics in the field of gynecologic cancer.